Sterling Capital Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$35.8K Sell
2,455
-1,492
-38% -$14.4K ﹤0.01% 1669
2026
Q1
$29.3K Sell
3,947
-2,861
-42% -$30.1K ﹤0.01% 1850
2025
Q4
$80.1K Sell
6,808
-1,277
-16% -$13.8K ﹤0.01% 1622
2025
Q3
$62.4K Buy
8,085
+4,917
+155% +$34.4K ﹤0.01% 1690
2025
Q2
$23.2K Buy
3,168
+1,134
+56% +$9.15K ﹤0.01% 1740
2025
Q1
$19.3K Sell
2,034
-1,672
-45% -$20.9K ﹤0.01% 1667
2024
Q4
$61.1K Buy
3,706
+3,289
+789% +$51.1K ﹤0.01% 1561
2024
Q3
$6.15K Buy
+417
New +$6.53K ﹤0.01% 1684

Other funds holding NEO

Sterling Capital Management's NEO Position: Q2 2026 in Review

Sterling Capital Management reduced its NeoGenomics (NEO) stake by 38% in Q2 2026, selling an estimated $14.4K and leaving 2,455 shares worth $35.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

Sterling Capital Management first reported a position in NEO in Q3 2024 and has held it in 8 quarters since. The position peaked at $80.1K in Q4 2025. 57 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • Sterling Capital Management held 2,455 shares of NeoGenomics worth $35.8K as of Q2 2026.
  • Sterling Capital Management sold 1,492 NeoGenomics shares in Q2 2026, an estimated $14.4K.
  • NeoGenomics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1669 holding.
  • Sterling Capital Management first reported a position in NeoGenomics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's NeoGenomics position peaked at $80.1K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.